Prevalence and Impact of Pertussis and RSV on Asthma Severity and Control

Launched by HOSPITAL CLINICO UNIVERSITARIO DE SANTIAGO · Feb 22, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how common infections like whooping cough (caused by Bordetella pertussis) and respiratory syncytial virus (RSV) affect people with asthma. The researchers want to find out how often these infections occur in adults with asthma and how they impact asthma symptoms over time. The study will take place in 35 medical centers across Spain and will involve patients reporting any worsening of their asthma or respiratory symptoms over a period of two years.

To participate in this study, you need to be an adult aged 18 or older with a diagnosis of asthma for at least one year. You should be able to follow the study guidelines, which include providing samples for testing if you have symptoms. However, if you've had whooping cough or a respiratory infection recently, or if you have other significant health issues, you may not be eligible. Participants will have regular check-ins and will help researchers gather important information about how these infections affect asthma control. Your involvement could help improve understanding and treatment for asthma patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patient (age 18 years and over)
• • Diagnosed with asthma at least one year prior to the date of enrolment.
• • Patients who, in the opinion of the investigator, can and will comply with the requirements of the study protocol for the duration of the follow-up period (e.g. agree to provide samples for testing, able to attend for testing upon asthma exacerbation and/or ARI symptoms occurring)
• • Patients who are able to provide written informed consent.
• Exclusion Criteria:
• • Patients with a prior history of pertussis in the last 12 months
• • Patients with ARI within the 2 weeks prior to enrolment
• • Patients who have another respiratory disease other than asthma, alcohol or drug abuse at the time of being included in the study, or an active oncological disease (patients in treatment or follow-up for oncological disease) or pregnant women.
• • Patients treated with immunosuppressive or immunomodulating agents not related to asthma diagnosis. will be excluded.
• • Patients vaccinated for RSV will be also excluded (NOTE: -Patients that have received an RSV (investigational) vaccine or medicine for any of the above, should be excluded from the study from the beginning. Patients that might be vaccinated in the upcoming years, while the study is still ongoing, can enrol. However, from the moment they receive a vaccine, they should be excluded and no additional data will be collected. Data collected during the study up until the time of vaccination will still be included in the analysis).
• • Patients vaccinated for B. Pertussis during the previous 12 months will be also excluded.
• • Patients who plan to move during the study period will be excluded.